Impact of vericiguat on mortality and hospitalization in HFrEF: a systematic review, meta‑analysis, and meta-regression
Authors: Ihab Suliman , Noor Yousef Al-Mohaimeed , Hisham Ali Hendi Alghamdi , Saja Abdullah Alharbi , Leen Ghazi Alahmadi , Sabah Hussein Alkharboush , Layan Tareq Aldhowayan , Manahel Hayder H. Alawami , Abdulrahman Mohammed H. M. Aldousari , Salah J. S. A. A. Alrashidi , Rahaf Mohammed Alansari
Abstract
Background: Patients with heart failure with reduced ejection fraction (HFrEF) remain at high risk despite guideline‑directed therapy. Vericiguat, an oral soluble guanylate cyclase stimulator, has emerged as a novel option. We conducted a systematic review and meta‑analysis to evaluate its efficacy and safety.
Methods: Randomized, double‑blind, placebo‑controlled trials of vericiguat in adults with chronic HFrEF were identified through November 2025. The primary outcome was cardiovascular (CV) death or heart failure (HF) hospitalization; secondary outcomes included CV death, HF hospitalization, all‑cause mortality, and safety endpoints.
Results: Three trials enrolling >11,000 patients were analyzed. Vericiguat reduced the composite of CV death or HF hospitalization (RR 0.91, 95% CI 0.86–0.97) and lowered HF hospitalization risk, including recurrent events. All‑cause mortality showed modest reduction, while CV mortality alone was not significantly reduced. Safety analyses revealed slightly higher risks of hypotension and anemia, but no excess syncope or kidney injury.
Conclusion: Vericiguat offers modest but clinically relevant benefits in reducing heart failure hospitalizations and composite cardiovascular outcomes in HFrEF. Its safety profile is generally acceptable, with only slight increases in hypotension and anemia. These findings support its role as an adjunctive therapy for selected high‑risk patients.
Keywords: Vericiguat, heart failure with reduced ejection fraction (HFrEF), heart failure hospitalization, cardi‑ ovascular outcomes, meta‑analysis.
Pubmed Style
Ihab Suliman, Noor Yousef Al-Mohaimeed, Hisham Ali Hendi Alghamdi, Saja Abdullah Alharbi, Leen Ghazi Alahmadi, Sabah Hussein Alkharboush, Layan Tareq Aldhowayan, Manahel Hayder H. Alawami, Abdulrahman Mohammed H. M. Aldousari, Salah J. S. A. A. Alrashidi, Rahaf Mohammed Alansari. Impact of vericiguat on mortality and hospitalization in HFrEF: a systematic review, meta‑analysis, and meta-regression. AMEM. 2026; 08 (November 2026): -. doi:10.24911/amem.15-3231
Publication History
Received: October 06, 2026
Revised: October 15, 2026
Accepted: October 21, 2026
Published: November 08, 2026
Authors
Ihab Suliman
Cardiology, King Abdulaziz Medical City, King Abdulaziz Cardiac Center, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia.
Noor Yousef Al-Mohaimeed
College of Medicine, Qassim University, Buraydah, Saudi Arabia.
Hisham Ali Hendi Alghamdi
Faculty of Medicine, Al Baha University, Al Baha, Saudi Arabia.
Saja Abdullah Alharbi
College of Medicine, Majmaah University, Majmaah, Saudi Arabia.
Leen Ghazi Alahmadi
College of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
Sabah Hussein Alkharboush
Faculty of Medicine, University of Tabuk, Tabuk, Saudi Arabia.
Layan Tareq Aldhowayan
College of Medicine, Qassim University, Buraydah, Saudi Arabia.
Manahel Hayder H. Alawami
College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.
Abdulrahman Mohammed H. M. Aldousari
Department of Internal Medicine, Farwaniya Hospital, Ministry of Health, Farwaniya, Kuwait.
Salah J. S. A. A. Alrashidi
Department of Internal Medicine, Al Sabah Medical Hospital, Ministry of Health, Kuwait City, Kuwait.
Rahaf Mohammed Alansari
Faculty of Medicine, University of Tabuk, Tabuk, Saudi Arabia.